Molecular and pharmacological determinants of the therapeutic response to artemether-lumefentrine in multidrug-resistant Plasmodium falciparum malaria

Clinical Infectious Diseases

Volumn 42, Issue 11, 2006, Pages 1570-1577

  Price, Rie N ^a,c   Uhlemann, Anne Catrin ^b   Van Vugt, Michela ^d   Brockman, Al ^c,d   Hutagalung, Robert ^d   Nair, Shalini ^f   Nash, Denae ^f   Singhasivanon, Pratap ^e   Anderson, Tim J C ^f   Krishna, Sanjeev ^b   White, Nicholas J ^a,e   Noston, François ^a,d,e  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^d SHOKLO MALARIA RESEARCH UNIT   (Thailand)

^e MAHIDOL UNIVERSITY   (Thailand)

^f SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; ARTESUNATE; HALOFANTRINE; MEFLOQUINE; QUININE;

ADOLESCENT; ARTICLE; CHILD; CONCENTRATION RESPONSE; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; FEMALE; GENE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALARIA; MALE; MOLECULAR BIOLOGY; MULTIDRUG RESISTANCE; PFMDR1 GENE; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; SENSITIVITY AND SPECIFICITY; THAILAND; TREATMENT FAILURE;

ADOLESCENT; ADULT; ANIMALS; ANTIMALARIALS; ARTEMISININS; ATP-BINDING CASSETTE TRANSPORTERS; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; FLUORENES; HUMANS; MALARIA, FALCIPARUM; MALE; PLASMODIUM FALCIPARUM; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTOZOAN PROTEINS;

EID: 33646736568     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/503423     Document Type: Article

References (29)

1. Price RN, Nosten F. Drug resistant falciparum malaria: clinical consequences and strategies for prevention. Drug Resist Updat 2001; 4: 187-96.
2. Ezzet F, van Vugt M, Nosten F, Looareesuwan S, White NJ. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother 2000; 44:697-704.
3. Vugt MV, Wilairatana P, Gemperli B, et al. Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria. Am J Trop Med Hyg 1999; 60:936-42.
4. Lefevre G, Looareesuwan S, Treeprasertsuk S, et al. A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg 2001; 64:247-56.
5. van Vugt M, Looareesuwan S, Wilairatana P, et al. Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria. Trans R Soc Trop Med Hyg 2000; 94:545-8.
6. ter Kuile FO, Dolan G, Nosten F, et al. Halofantrine versus mefloquine in treatment of multidrug-resistant falciparum malaria. Lancet 1993; 341:1044-9.
7. Price RN, Uhlemann AC, Brockman A, et al. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 2004; 364:438-47.
8. Duraisingh MT, Roper C, Walliker D, Warhurst DC. Increased sensitivity to the antimalarials mefloquine and artemisinin is conferred by mutations in the pfmdr1 gene of Plasmodium falciparum. Mol Microbiol 2000; 36:955-61.
9. van Vugt M, Brockman A, Gemperli B, et al. Randomized comparison of artemether-benflumetol and artesunate-mefloquine in treatment of multidrug-resistant falciparum malaria. Antimicrob Agents Chemother 1998; 42:135-9.
10. Luxemburger C, Thwai KL, White NJ, et al. The epidemiology of malaria in a Karen population on the western border of Thailand. Trans R Soc Trop Med Hyg 1996; 90:105-11.
11. Anderson TJ, Nair S, Qin H, et al. Are transporter genes other than the chloroquine resistance locus (pfcrt) and multidrug resistance gene (pfmdr) associated with antimalarial drug resistance? Antimicrob Agents Chemother 2005; 49:2180-8.
12. Brockman A, Price RN, van Vugt M, et al. Plasmodium falciparum antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate-mefloquine. Trans R Soc Trop Med Hyg 2000; 94:537-44.
13. Brockman A, Paul RE, Anderson TJ, et al. Application of genetic markers to the identification of recrudescent Plasmodium falciparum infections on the northwestern border of Thailand. Am J Trop Med Hyg 1999; 60:14-21.
14. Price RN, Cassar C, Brockman A, et al. The pfmdr1 gene is associated with a multidrug-resistant phenotype in Plasmodium falciparum from the western border of Thailand. Antimicrob Agents Chemother 1999; 43:2943-9.
15. Duraisingh MT, Jones P, Sambou I, von Seidlein L, Pinder M, Warhurst DC. The tyrosine-86 allele of the pfmdr1 gene of Plasmodium falciparum is associated with increased sensitivity to the anti-malarials mefloquine and artemisinin. Mol Biochem Parasitol 2000; 108: 13-23.
16. Stepniewska K, White NJ. Design and interpretation of antimalarial drug trials in uncomplicated falciparum malaria. Antimicrob Agents Chemother (in press).
17. Price RN, Nosten F, Luxemburger C, et al. Artesunate/mefloquine treatment of multi-drug resistant falciparum malaria. Trans R Soc Trop Med Hyg 1997; 91:574-7.
18. ter Kuile FO, Nosten F, Luxemburger C, et al. Mefloquine treatment of acute falciparum malaria: a prospective study of non-serious adverse effects in 3673 patients. Bull World Health Organ 1995; 73: 631-42.
19. White NJ. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother 1997; 41:1413-22.
20. White NJ, van Vugt M, Ezzet F. Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine. Clin Pharmacokinet 1999; 37:105-25.
21. van Agtmael M, Bouchaud O, Malvy D, et al. The comparative efficacy and tolerability of CGP 56697 (artemether + lumefantrine) versus halofantrine in the treatment of uncomplicated falciparum malaria in travellers returning from the Tropics to The Netherlands and France. Int J Antimicrob Agents 1999; 12:159-69.
22. Mutabingwa TK, Anthony D, Heller A, et al. Amodiaquine alone, amodiaquine+sulfadoxine-pyrimethamine, amodiaquine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. Lancet 2005; 365:1474-80.
23. Piola P, Fogg C, Bajunirwe F, et al. Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial. Lancet 2005; 365:1467-73.
24. Ezzet F, Mull R, Karbwang J. Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients. Br J Clin Pharmacol 1998; 46:553-61.
25. Nelson AL, Purfield A, McDaniel P, et al. pfmdr1 Genotyping and in vivo mefloquine resistance on the Thai-Myanmar border. Am J Trop Med Hyg 2005; 72:586-92.
26. Martensson A, Stromberg J, Sisowath C, et al. Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania. Clin Infect Dis 2005;41:1079-86.
27. Hastings IM, Ward SA. Coartem (artemether-lumefantrine) in Africa: the beginning of the end? J Infect Dis 2005; 192:1303-4.
28. Sutherland CJ, Alloueche A, Curtis J, et al. Gambian children successfully treated with chloroquine can harbor and transmit Plasmodium falciparum gametocytes carrying resistance genes. Am J Trop Med Hyg 2002; 67:578-85.
29. Kublin JG, Cortese JF, Njunju EM, et al. Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. J Infect Dis 2003; 187:1870-5.